139 related articles for article (PubMed ID: 24166106)
1. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Joerger M; Huitema AD; Koeberle D; Rosing H; Beijnen JH; Hitz F; Cerny T; Schellens JH; Gillessen S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):113-24. PubMed ID: 24166106
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
[TBL] [Abstract][Full Text] [Related]
5. Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Roviello F; Marrelli D; Francini E
Anticancer Drugs; 2015 Jul; 26(6):682-6. PubMed ID: 25811963
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Santini D; Virzi V; Vasile E; Vincenzi B; Catalano V; Graziano F; Masi G; Bronte G; Russo A; Falcone A; Tonini G
Oncology; 2012; 82(2):75-82. PubMed ID: 22327844
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Pino MS; Milella M; Gelibter A; Sperduti I; De Marco S; Nuzzo C; Bria E; Carpanese L; Ruggeri EM; Carlini P; Cognetti F
Oncology; 2009; 76(4):254-61. PubMed ID: 19246950
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Tan BR; Brenner WS; Picus J; Marsh S; Gao F; Fournier C; Fracasso PM; James J; Yen-Revollo JL; McLeod HL
Ann Oncol; 2008 Oct; 19(10):1742-8. PubMed ID: 18534963
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
12. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction.
Shibata T; Ebata T; Fujita K; Shimokata T; Maeda O; Mitsuma A; Sasaki Y; Nagino M; Ando Y
Cancer Sci; 2016 Feb; 107(2):168-72. PubMed ID: 26595259
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
14. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Koeberle D; Saletti P; Borner M; Gerber D; Dietrich D; Caspar CB; Mingrone W; Beretta K; Strasser F; Ruhstaller T; Mora O; Herrmann R;
J Clin Oncol; 2008 Aug; 26(22):3702-8. PubMed ID: 18669455
[TBL] [Abstract][Full Text] [Related]
16. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Hess V; Salzberg M; Borner M; Morant R; Roth AD; Ludwig C; Herrmann R
J Clin Oncol; 2003 Jan; 21(1):66-8. PubMed ID: 12506172
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK; Holen KD; Schelman WR; Mulkerin DL; Deming DA; Hernan HR; Traynor AM; Goggins T; Groteluschen D; Oettel K; Robinson E; Lubner SJ
Invest New Drugs; 2013 Aug; 31(4):943-8. PubMed ID: 23263993
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Mambrini A; Pacetti P; Del Freo A; Seta RD; Pezzuolo D; Torri T; Orlandi M; Tartarini R; Cantore M
Anticancer Res; 2009 May; 29(5):1547-9. PubMed ID: 19443364
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Schilsky RL; Bertucci D; Vogelzang NJ; Kindler HL; Ratain MJ
J Clin Oncol; 2002 Jan; 20(2):582-7. PubMed ID: 11786589
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
